Compare Cytokinetics Inc (CYTK) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Royal Bank of Canada — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while Royal Bank of Canada trades at $215.03 (market cap $294.58B). The key difference: Royal Bank of Canada is far larger — about 26.5× Cytokinetics Inc's market cap, and Royal Bank of Canada pays a 2.38% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | RY | |
|---|---|---|
Market Cap | $11.12B | $294.58B |
Sector | Technology | Financials |
52-Week High | $87.26 | $214.04 |
52-Week Low | $33.23 | $128.46 |
Enterprise Value | $11.59B | — |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Royal Bank of Canada (RY) trades at $210.69, down 0.19% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a P/E of 19.45, net income margin of 31.85%, and ROE of 17.17%. Recent Q2 2026 earnings of $2.84 per share exceeded expectations, and the company announced a dividend increase to $1.76 per share alongside a share repurchase program.
RY's outlook is supported by robust profitability and shareholder returns, but risks include a high P/B ratio of 3.21 and macroeconomic sensitivity. Analyst sentiment is mixed with a slight hold bias, yet the stock's technical strength and dividend growth present a compelling case for income-focused investors amid cautious market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
